Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant QL1706 plus chemotherapy for stage II–III NSCLC
ChiCTR2500102918Phase 2Not yet recruiting
- Sponsor
- Zhangzhou Municipal Hospital of Fujian Province
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in non-small cell lung cancer (NSCLC), sponsored by Zhangzhou Municipal Hospital of Fujian Province. Primary endpoint: Pathological complete response rate. Planned start May 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500102918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102918.